Wegovy and liver function: what we know, what's uncertain, and who to ask

The common misconception: that weight-loss injections put the liver under strain

Plenty of people starting Wegovy wonder whether a medicine processed by the body could tax a liver that is already working hard. It is a reasonable concern. If you want to understand how Wegovy affects liver function, the evidence does not support concern for most patients with healthy or mildly affected liver function, and for some liver conditions the picture is notably more positive than people expect.

On 3 July 2026, the MHRA granted semaglutide a conditional approval to treat MASH (metabolic dysfunction-associated steatohepatitis) in adults with moderate-to-advanced liver fibrosis. The MHRA's announcement confirmed this as a standalone licensed indication, separate from weight management. MASH is one of the more serious forms of fatty liver disease, characterised by inflammation and scarring, and it has historically had very limited treatment options. This approval matters because it shifts the conversation: rather than asking whether Wegovy affects the liver at all, there is now a formal regulatory answer that it can help a specific group of patients with liver disease.

What drove that approval was trial evidence showing semaglutide reduced liver-fat accumulation, lowered markers of liver inflammation and slowed fibrosis progression in eligible participants. The weight loss itself contributes to this: fatty liver disease is closely linked to excess visceral fat, and meaningful weight reduction tends to ease the burden on the liver. These two effects, the direct metabolic action of semaglutide and the secondary benefit of sustained weight loss, appear to work together.

For more on the relationship between semaglutide and liver outcomes, the liver effects of Wegovy page goes into further detail.

Where genuine uncertainty still exists: severe liver impairment

The approval and the positive trial data do not mean Wegovy is appropriate for every patient with liver disease. There is an important distinction between fatty liver conditions, where the evidence is encouraging, and severe hepatic impairment, where it is thinner.

The prescribing information for semaglutide notes that patients with severe liver impairment have not been extensively studied, and caution is warranted. The liver plays a central role in how medicines are broken down and cleared; when its function is substantially reduced, the pharmacokinetics of a drug can change in ways that affect both efficacy and tolerability. A prescriber reviewing liver function tests and medical history will weigh this up individually.

Mild-to-moderate liver impairment does not appear to require dose adjustment based on available data, but this is not the same as saying it is categorically without consideration. If a patient has abnormal liver function tests for a reason other than fatty liver disease, the underlying cause matters just as much as the number on the page. Autoimmune hepatitis, viral hepatitis and other conditions introduce variables that a clinical assessment has to account for.

The NHS sets out the overall safety profile of semaglutide, including conditions that require prescriber discussion, on the NHS semaglutide page. Anyone with a known liver condition should bring their most recent blood results to any consultation, whether NHS or private.

Pancreatitis, abdominal symptoms, and why the distinction matters here

One safety signal that intersects with liver-function queries is pancreatitis. The pancreas and liver share anatomical proximity and biliary connections; gallstones, which can be associated with rapid weight loss, can affect both. In January 2026, the MHRA issued a Drug Safety Update reinforcing that acute pancreatitis is a known, infrequent but serious risk with GLP-1 medicines including semaglutide.

The specific warning signs are severe stomach pain that does not ease, often spreading towards the back, sometimes accompanied by vomiting. This is not a symptom to manage at home. Anyone experiencing it whilst on Wegovy should stop treatment and seek urgent medical attention. The MHRA's Yellow Card scheme allows patients and clinicians to report suspected side effects, which contributes to ongoing safety monitoring of these medicines.

It is worth keeping this separate from the liver-function question: pancreatitis and liver disease are distinct conditions that can sometimes be confused because both produce upper abdominal symptoms. If there is any doubt about what is causing abdominal pain in a patient on Wegovy, a doctor should assess it the same day.

Abdominal discomfort from nausea or indigestion, the far more common GLP-1 side effects, typically relates to gastric emptying changes. For context on other ways Wegovy interacts with digestion, including food and drink choices, the guidance on carbonated drinks during treatment covers one practical aspect some patients overlook.

Who to talk to, and how a clinical review handles this

Wegovy for weight management in adults requires a BMI of 30 or above, or 27 or above alongside a weight-related health condition, alongside a reduced-calorie diet and increased activity. But BMI criteria are only part of what a prescriber considers. Pre-existing conditions, current medications, and relevant blood results, including liver function tests, all feed into the clinical picture. If you have fatty liver disease, your situation may actually make a stronger case for treatment; if you have severe hepatic impairment from another cause, your prescriber may want specialist input first.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. That review does not happen in batch or overnight: our clinical team, led by our clinical director, assesses each application the same day it is submitted. You can review the treatment options we offer and the consultation process before committing to anything. There is no charge for the consultation itself.

If you have been told your liver function tests are abnormal and you are unsure whether Wegovy is an option, the clearest route is to raise it directly in your consultation, ideally with your most recent results to hand. Tucking a printed copy into the drawer where you keep your daily pill organiser is a small habit that tends to mean it's actually there when you need it. Our prescribers will tell you plainly whether private treatment is appropriate or whether a GP or hepatologist should be involved first. The effects of Wegovy on the liver page also pulls together the clinical evidence if you want to read further before your consultation.